Search
Now showing items 1-7 of 7
What Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review
(2021-10-28)
With prevalence high and rising given the close relationship with obesity and diabetes mellitus, non-alcoholic fatty liver disease (NAFLD) is progressively becoming the most common chronic liver condition worldwide. However, ...
Risk factors for persistent enterococcal bacteraemia: a multicentre retrospective study
(2022-06)
Objectives
Conditions favouring persistent enterococcal bacteraemia (p-EB) have not been fully investigated yet. The aim of our study is to analyse risk factors for p-EB and its impact on mortality.
Methods
International ...
Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons
(2023-02)
Non-alcoholic fatty liver disease is a condition that affects 25% of the population. Non-alcoholic steatohepatitis (NASH) is a progressive form of the disease that can lead to severe complications such as cirrhosis and ...
Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints
(2023-03-09)
Non-alcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and a disease with high unmet medical need. Platform trials provide great benefits for sponsors and trial participants ...
Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
(2022-08)
Background & Aims
Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non-alcoholic steatohepatitis (NASH) is largely unknown in the general ...
Morbilidad metabólica en la población penitenciaria de Cataluña
(2023-06)
Objective
To investigate the prevalence of metabolic morbidity (MM) amongst prison inmates.
Design
Multicentric, cross-sectional observational study.
Setting
All (nine) prisons in Catalonia.
Participants
Convicted ...